Insider Buying: Pulse Biosciences, Inc. (NASDAQ:PLSE) Director Buys 56,054 Shares of Stock

Pulse Biosciences, Inc. (NASDAQ:PLSE) Director Robert W. Duggan bought 56,054 shares of the business’s stock in a transaction dated Wednesday, December 11th. The shares were acquired at an average cost of $17.35 per share, for a total transaction of $972,536.90. Following the transaction, the director now directly owns 42,228,057 shares in the company, valued at approximately $732,656,788.95. This represents a 0.13 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website.

Pulse Biosciences Trading Up 3.0 %

PLSE opened at $17.65 on Friday. The business’s 50-day simple moving average is $17.68 and its 200-day simple moving average is $16.40. Pulse Biosciences, Inc. has a one year low of $6.59 and a one year high of $22.69.

Pulse Biosciences (NASDAQ:PLSE) last announced its earnings results on Wednesday, October 30th. The company reported ($0.21) EPS for the quarter. During the same quarter last year, the business earned ($0.19) EPS.

Institutional Investors Weigh In On Pulse Biosciences

Hedge funds have recently made changes to their positions in the business. Quest Partners LLC purchased a new position in Pulse Biosciences in the 2nd quarter valued at $91,000. Price T Rowe Associates Inc. MD acquired a new position in shares of Pulse Biosciences during the first quarter worth about $88,000. Cetera Advisors LLC purchased a new stake in Pulse Biosciences in the 1st quarter valued at approximately $109,000. Creative Planning increased its position in Pulse Biosciences by 113.9% during the 3rd quarter. Creative Planning now owns 21,910 shares of the company’s stock worth $384,000 after purchasing an additional 11,667 shares during the period. Finally, Franklin Resources Inc. acquired a new stake in shares of Pulse Biosciences in the 3rd quarter valued at approximately $378,000. Institutional investors and hedge funds own 76.95% of the company’s stock.

Analysts Set New Price Targets

Separately, StockNews.com raised shares of Pulse Biosciences to a “sell” rating in a report on Thursday.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.